BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 ...

Q4 2025 earnings call: record $589M revenue, 2026 guidance, FIRDAPSE/AGAMREE growth drivers, and key risks—read now.

Mahenge is one of the more advanced large-flake graphite projects globally. It has a resource estimate of 213Mt at 7.8% TGC, ...

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained ...

Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 mil ...

I would now like to turn the conference over to Mariann Ohanesian, Senior Director of IR for Puma Biotechnology. You may begin your conference. Thank you, Sherry. Good afternoon, and welcome to Puma's ...

TECHNIP ENERGIES FY 2025 FINANCIAL RESULTS A successful year of delivery; trending ahead of medium-term outlook Highest-ever revenue of €7.2bn and EBITDA of €638m; industry-leading profitability ...

As an early spring thaw settles over Lake Geneva, the Palais des Nations, home to the United Nations Office at Geneva, is ...

And he’s on tap to do the same again today when he headlines a Toronto business luncheon — at exactly the same hour IERRE POILIEVRE takes the stage at a different downtown hotel to reveal his vision ...